ClinicalTrials.gg
Status unknownNCT03851432Updated Jul 16, 2020

Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin

A Phase 3 interventional study of Janagliflozin plus metformin and Janagliflozin plus metformin in Diabetes Mellitus, Type 2, sponsored by Sihuan Pharmaceutical Holdings Group Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by Sihuan Pharmaceutical Holdings Group Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Planned enrollment
58th of 287
390 · median 100
Started
2019
with 4 others
Phase 3
72 of 293
1 open now
Registered
242nd of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 58th largest by planned enrollment of the 287 interventional ones that give a count, is one of 5 that started in 2019, is one of 72 in phase 3, and was the 242nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Janagliflozin compared to placebo, both in combination with Metformin, in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with Metformin alone.

Read the detailed description

A multicentre, randomized, double-blind, placebo-controlled, parallel-group study (a 24-week core period followed by a 28-week extension period), to evaluate the efficacy and safety of Janagliflozin (25 mg and 50 mg) compared to placebo, all in combination with Metformin, in patients diagnosed with T2DM who are not achieving an adequate response from Metformin monotherapy. Approximately 390 patients with inadequate glycemic control with Metformin monotherapy will receive once-daily double-blind treatment with Janagliflozin 25 mg or 50 mg , both in combination with Metformin , for 52 weeks, or receive 24 weeks of double-blind treatment with placebo in combination with Metformin followed by 28 weeks of single-blind treatment with Janagliflozin 25 mg or 50 mg, both in combination with Metformin. During the treatment, if a patient's glycemic level remains high despite treatment with study drug and reinforcement with diet and exercise, the patient will receive treatment with Linagliptin (rescue therapy) consistent with local prescribing information.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T2DM Patients with inadequate glycemic control ( level≥7.0% and ≤10.5% at baseline) on metformin monotherapy.
  • : 18.0\~35.0 kg/m2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus (T1DM), diabetes caused by pancreatic injury, or secondary diabetes (e.g., diabetes caused by Cushing's syndrome or acromegaly)
  • More than 10% change in body weight within the 3 months before screening
  • Any laboratory test indicators meet the following standards:

    • fasting plasma glucose ≥ 15 mmol/L
    • , alanine aminotransferase levels > 3 times the (ULN); total > 1.5 times ULN
    • \< 100 g/L
    • \< 60 mL/min/1.73m2
    • fasting triglycerides > 5.64 mmol/L (500 mg/dL)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Janagliflozin 25 mg plus metformin

    Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)

    Drug: Janagliflozin plus metformin

  • Experimental
    Janagliflozin 50 mg plus metformin

    Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)

    Drug: Janagliflozin plus metformin

  • Placebo comparator
    Placebo/Janagliflozin plus metformin

    In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.

    Device: Placebo plus metformin

Interventions

  • DrugJanagliflozin plus metformin

    Drug pages: Janagliflozin · Metformin

    Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.

  • DrugJanagliflozin plus metformin

    Drug pages: Janagliflozin · Metformin

    Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.

  • DevicePlacebo plus metformin

    Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period)

    To examine whether the mean change in HbA1c from Baseline to Week 24 with Janagliflozin is superior to placebo

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change in HbA1c From Baseline to Week 52

    To compare the mean change in HbA1c from Baseline to Week 52 between groups

    Time frame: Baseline and Week 52

  2. Percentage of Patients With HbA1c <7% at Week 24 (Core period) and Week 52 (Extension period)

    To compare the percentage of patients with HbA1c \<7% at Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Week 24 and week 52

  3. Percentage of Patients With HbA1c <6.5% at Week 24 (Core period) and Week 52 (Extension period)

    To compare the percentage of patients with HbA1c \<6.5% at week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  4. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in fasting plasma glucose (FPG) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  5. Change in 2-hour Post-prandial Glucose From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in 2-hour post-prandial glucose from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  6. Change in Blood Lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in blood lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  7. Change in Blood Pressure (systolic blood pressure and diastolic blood pressure) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in blood pressure (systolic blood pressure and diastolic blood pressure) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  8. Change in Body Weight From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in body weight from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  9. Change in Fasting C-peptide From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in fasting C-peptide from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  10. Change in Insulin Sensitivity From Baseline to Week 24 (Core period) and Week 52 (Extension period) by calculation Homeostasis model assessment-insulin resistance

    To compare the mean change in insulin sensitivity from Baseline to Week 24 (core period) and Week 52 (extension period) between group by calculation Homeostasis model assessment-insulin resistance

    Time frame: Baseline, Week 24 and Week 52

  11. Change in β-cell Function From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in β-cell function from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  12. Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period)

    To compare the percentage of patients who have received rescue therapy by Week 24 (core period) and Week 52 (extension period) between groups.

    Time frame: Baseline, Week 24 and Week 52

07

Study locations

1 of 1 sites recruiting
  • Linong Ji
    Beijing, Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Apr 2020, 10 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 22, 2019
StartActual
Jun 30, 2019
Primary completionActual
Apr 30, 2020
CompletionEst.
Dec 31, 2021
Last update
Jul 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03851432
Responsible party
Sponsor
First posted
Feb 22, 2019
Start date
Jun 30, 2019
Primary completion
Apr 30, 2020
Completion
Dec 31, 2021 (estimated)
Last update
Jul 16, 2020

Study contacts

Leili Gao, Doctor
Contact
plum_jj@sina.com
00861088325578 ext. 00861088325578
Linong Ji, Doctor
Contact
plum_jj@sina.com
00861088325578 ext. 00861088325578

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Janagliflozin · Metformin

Start the discussion